AKT1 and cholangiocarcinoma: Inhibition of interleukin-6 has been reported to specifically pose a growth-inhibition effect on cholangiocarcinoma cell line, and interleukin-6 overexpression will lead to activation of AKT and anti-apoptotic protein myeloid cell leukemia-1 [51].